Literature DB >> 29170871

The diagnostic role of PTEN and ARID1A in serous effusions.

Ben Davidson1,2, Maurizio Pinamonti3, Dolors Cuevas4, Arild Holth5, Pio Zeppa6, Thomas Hager7, Jeremias Wohlschlaeger7, Martin Tötsch8.   

Abstract

The aim of this study was to analyze the diagnostic role of PTEN and ARID1A in effusion cytology. Effusions (n = 279), consisting of 226 carcinomas (70 ovarian, 64 breast, 36 lung, and 15 uterine corpus carcinomas; 41 carcinomas of other origin) and 53 malignant mesotheliomas, were analyzed for PTEN and ARID1A expression using immunohistochemistry. PTEN was preserved in 166 (59%) tumors, partially lost in 38 (14%), and absent in 75 (27%), with lower expression in malignant mesotheliomas compared to carcinomas, though not significantly (p = 0.084). ARID1A was preserved in 243 (88%) tumors, partially lost in 18 (6%), and absent in 18 (6%). The majority of tumors with absent ARID1A were ovarian carcinomas, predominantly of clear cell or low-grade serous type. Reactive mesothelial cells in carcinoma specimens were uniformly positive for both proteins. ARID1A mutation analysis showed no mutations in eight analyzed specimens negative by immunohistochemistry. Loss of PTEN and ARID1A expression is highly specific for malignancy in effusion pathology. Loss of PTEN is not informative of organ of origin, whereas absence of ARID1A should raise suspicion of an ovarian primary.

Entities:  

Keywords:  ARID1A; Diagnosis; Effusions; Immunohistochemistry; PTEN

Mesh:

Substances:

Year:  2017        PMID: 29170871     DOI: 10.1007/s00428-017-2273-1

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  36 in total

1.  Is PAX2 a reliable marker in differentiating diffuse malignant mesotheliomas of peritoneum from serous carcinomas of müllerian origin?

Authors:  Faye F Gao; Alyssa M Krasinskas; Mamatha Chivukula
Journal:  Appl Immunohistochem Mol Morphol       Date:  2012-05

2.  Tau and PTEN status as predictive markers for response to trastuzumab and paclitaxel in patients with HER2-positive breast cancer.

Authors:  Dong-Hoe Koo; Hee Jin Lee; Jin-Hee Ahn; Dok Hyun Yoon; Sung-Bae Kim; Gyungyub Gong; Byung Ho Son; Sei Hyun Ahn; Kyung Hae Jung
Journal:  Tumour Biol       Date:  2015-03-01

3.  Biomarker-based ovarian carcinoma typing: a histologic investigation in the ovarian tumor tissue analysis consortium.

Authors:  Martin Köbel; Steve E Kalloger; Sandra Lee; Máire A Duggan; Linda E Kelemen; Leah Prentice; Kimberly R Kalli; Brooke L Fridley; Daniel W Visscher; Gary L Keeney; Robert A Vierkant; Julie M Cunningham; Christine Chow; Roberta B Ness; Kirsten Moysich; Robert Edwards; Francesmary Modugno; Clareann Bunker; Eva L Wozniak; Elizabeth Benjamin; Simon A Gayther; Aleksandra Gentry-Maharaj; Usha Menon; C Blake Gilks; David G Huntsman; Susan J Ramus; Ellen L Goode
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-07-23       Impact factor: 4.254

4.  Hepatocyte nuclear factor-1β is not a specific marker of clear cell carcinoma in serous effusions.

Authors:  Ben Davidson
Journal:  Cancer Cytopathol       Date:  2013-09-24       Impact factor: 5.284

Review 5.  PTEN proteoforms in biology and disease.

Authors:  Prerna Malaney; Vladimir N Uversky; Vrushank Davé
Journal:  Cell Mol Life Sci       Date:  2017-03-13       Impact factor: 9.261

6.  Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma.

Authors:  Suzanne George; Diana Miao; George D Demetri; Dennis Adeegbe; Scott J Rodig; Sachet Shukla; Mikel Lipschitz; Ali Amin-Mansour; Chandrajit P Raut; Scott L Carter; Peter Hammerman; Gordon J Freeman; Catherine J Wu; Patrick A Ott; Kwok-Kin Wong; Eliezer M Van Allen
Journal:  Immunity       Date:  2017-02-21       Impact factor: 31.745

7.  The diagnostic role of claudins in serous effusions.

Authors:  Lilach Kleinberg; Arild Holth; Eduard Fridman; Ignat Schwartz; Ie-Ming Shih; Ben Davidson
Journal:  Am J Clin Pathol       Date:  2007-06       Impact factor: 2.493

8.  Value of PAX8, PAX2, claudin-4, and h-caldesmon immunostaining in distinguishing peritoneal epithelioid mesotheliomas from serous carcinomas.

Authors:  Nelson G Ordóñez
Journal:  Mod Pathol       Date:  2012-11-30       Impact factor: 7.842

Review 9.  ARID1A gene mutation in ovarian and endometrial cancers (Review).

Authors:  Takashi Takeda; Kouji Banno; Ryuichiro Okawa; Megumi Yanokura; Moito Iijima; Haruko Irie-Kunitomi; Kanako Nakamura; Miho Iida; Masataka Adachi; Kiyoko Umene; Yuya Nogami; Kenta Masuda; Yusuke Kobayashi; Eiichiro Tominaga; Daisuke Aoki
Journal:  Oncol Rep       Date:  2015-11-16       Impact factor: 3.906

10.  ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A.

Authors:  Chris T Williamson; Rowan Miller; Helen N Pemberton; Samuel E Jones; James Campbell; Asha Konde; Nicholas Badham; Rumana Rafiq; Rachel Brough; Aditi Gulati; Colm J Ryan; Jeff Francis; Peter B Vermulen; Andrew R Reynolds; Philip M Reaper; John R Pollard; Alan Ashworth; Christopher J Lord
Journal:  Nat Commun       Date:  2016-12-13       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.